Drugs / Ribupatide
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07458269 | Mar 2026 → May 2027 expected | obesity disorder | Kailera | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07709910 | Jul 2026 → Nov 2028 expected | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07284901 | Jan 2026 → Mar 2028 expected | obesity disorder | Kailera | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ribupatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284901 ↗ |
| Route | Subcutaneous | “SC Injection” NCT07284901 ↗ |